Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RRM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RRM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RRM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RRM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RRM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RRM1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RRM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:00091122 | Liver | HCC | nucleobase metabolic process | 28/7958 | 34/18723 | 2.21e-06 | 2.99e-05 | 28 |
GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
GO:001021221 | Liver | HCC | response to ionizing radiation | 89/7958 | 148/18723 | 1.10e-05 | 1.26e-04 | 89 |
GO:00062062 | Liver | HCC | pyrimidine nucleobase metabolic process | 15/7958 | 16/18723 | 2.55e-05 | 2.66e-04 | 15 |
GO:00092621 | Liver | HCC | deoxyribonucleotide metabolic process | 31/7958 | 44/18723 | 1.63e-04 | 1.30e-03 | 31 |
GO:00725271 | Liver | HCC | pyrimidine-containing compound metabolic process | 49/7958 | 82/18723 | 1.20e-03 | 6.68e-03 | 49 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
GO:0051262 | Liver | HCC | protein tetramerization | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
GO:0051290 | Liver | HCC | protein heterotetramerization | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
GO:0051291 | Liver | HCC | protein heterooligomerization | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
GO:00102128 | Oral cavity | OSCC | response to ionizing radiation | 99/7305 | 148/18723 | 5.49e-12 | 2.08e-10 | 99 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RRM1 | SNV | Missense_Mutation | | c.613N>T | p.Leu205Phe | p.L205F | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
RRM1 | SNV | Missense_Mutation | novel | c.1880N>A | p.Arg627His | p.R627H | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.941) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | novel | c.562N>C | p.Glu188Gln | p.E188Q | P23921 | protein_coding | tolerated_low_confidence(0.09) | benign(0.125) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | | c.7N>T | p.Val3Leu | p.V3L | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RRM1 | SNV | Missense_Mutation | | c.251N>G | p.Ser84Cys | p.S84C | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.729) | TCGA-D8-A1XS-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
RRM1 | deletion | Frame_Shift_Del | novel | c.1415delN | p.Val472AlafsTer6 | p.V472Afs*6 | P23921 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RRM1 | SNV | Missense_Mutation | novel | c.739N>A | p.Gly247Arg | p.G247R | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.908) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RRM1 | SNV | Missense_Mutation | | c.979G>T | p.Asp327Tyr | p.D327Y | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | | c.2254N>G | p.Leu752Val | p.L752V | P23921 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | novel | c.2180G>A | p.Gly727Asp | p.G727D | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | VINORELBINE | VINORELBINE | 23038758,24647522 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | MOTEXAFIN GADOLINIUM | | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | CLOFARABINE | CLOFARABINE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL1200983 | GALLIUM NITRATE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL1096882 | FLUDARABINE PHOSPHATE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | CISPLATIN | CISPLATIN | 12917817 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | cytarabine | CYTARABINE | 24024897 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL467 | HYDROXYUREA | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | 178103428 | HYDROXYUREA | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | GTI-2501 | | |